insights_auto
LGND neden düştü? 2,37%?
Daha Ayrıntılı Bilgichevron_right
LGND:NASDAQ
Ligand Pharmaceuticals Inc
$308,79
arrow_downward
-2,37%(-7,48) 1G
13 Kas, 16:00:01 GMT-5 · USD
search
Tüm semboller
| Sembol | Fiyat | Değişiklik | Değişiklik % |
|---|
insights_autoLGND ile ilgili en önemli analizler oluşturuluyor...
Açık
$313,98
Yüksek
$314,79
Düşük
$308,59
Piy. değ.
6,18 Mr
Ort. hacim
219,42 B
İşlem Hacmi
135,79 B
F/K oranı
134,83
52 haftalık en yüksek
$326,63
52 haftalık en düşük
$175,89
HBK
$2,29
Beta
1,07
Tedavüldeki hisse senedi sayısı
20,00 Mn
Çalışan sayısı
47
Açık
$313,98
Yüksek
$314,79
Düşük
$308,59
Piy. değ.
6,18 Mr
Ort. hacim
219,42 B
İşlem Hacmi
135,79 B
F/K oranı
134,83
52 haftalık en yüksek
$326,63
52 haftalık en düşük
$175,89
HBK
$2,29
Beta
1,07
Tedavüldeki hisse senedi sayısı
20,00 Mn
Çalışan sayısı
47
Haberler
Web kaynaklarından ve haber iş ortaklarından
Investing.com Nigeria
·
14 saat önce
Form 144 LIGAND PHARMACEUTICALS INC For: 14 November By Investing.com
Profil
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
Ligand Pharmaceuticals Inc hakkında
CEO-
Çalışan Sayısı47
Kuruluş TarihiEyl 1987
Genel MerkezJupiter, Florida, Amerika Birleşik Devletleri
SektörHealth Care
Sektör-
Web Sitesiligand.com